India Animal Health Market (2025 - 2030)

Market Size & Trends

The India animal health market size was estimated at USD 1.97 billion in 2024 and is anticipated to grow at a CAGR of 13.9% from 2025 to 2030. Key factors expected to drive the market include growing government participation, rising product/ service launches, evolving regulatory scenario, emergence of startup culture, increasing R&D investments, and technological advancements. The industry is driven by robust government participation, strategic international partnerships, and localized outreach programs. These developments are laying the groundwork for a more resilient and efficient animal healthcare infrastructure across the country.

In March 2025, the Union Cabinet approved a revised Livestock Health and Disease Control Programme (LHDCP) with a budget of INR 3,880 crore (USD 453 Mn) for 2024-25 and 2025-26. The revamped scheme consists of three core components: the National Animal Disease Control Programme (NADCP), Livestock Health & Disease Control (LH&DC), and the newly launched Pashu Aushadhi initiative. Key focus elements include mass vaccinations, deployment of mobile veterinary units, and distribution of affordable generic veterinary medicines through PM-Kisan Samriddhi Kendras (Centers) and cooperatives.

Earlier, in January 2025, the Indian Council of Agricultural Research (ICAR) organized a large-scale Animal Health Camp under the Scheduled Caste Sub-Plan (SCSP). Executed by the ICAR-Indian Institute of Soil & Water Conservation, this initiative provided veterinary services, raised health awareness, and promoted best practices in marginalized farming communities.

In November 2024, the Indian government launched the 'Animal Health Security Strengthening in India for Pandemic Preparedness and Response' project. With a USD 25 million grant from the G20 Pandemic Fund and implementation support from the ADB, World Bank, and FAO, the initiative aims to upgrade laboratory infrastructure, improve disease surveillance, and modernize data systems. Completion is slated for August 2026.

In July 2024, a significant regulatory shift occurred when the Indian Pharmacopoeia Commission (IPC) eliminated the obsolete Target Animal Batch Safety Test (TABST). This move not only minimizes unnecessary animal suffering but also aligns India with international standards in veterinary vaccine testing, reinforcing a commitment to humane and scientifically robust practices.

In May 2024, a Memorandum of Understanding was signed between the Department of Animal Husbandry and Dairying (DAHD) and the United Nations Development Programme (UNDP). Under this agreement, a digital AI-enabled system will monitor vaccine stocks, distribution, and storage. Additionally, DAHD will leverage UNDP’s Animal Vaccine Intelligence Network (AVIN) to enhance stakeholder capabilities, support livestock insurance, and improve immunization coverage. These cohesive policy actions and field-level interventions signal a major shift in India’s approach to animal health, promising improved outcomes, expanded service reach, and a sustainable framework for veterinary care.

Market Concentration & Characteristics

The degree of innovation can be characterized by bringing in high impact. This can be attributed to the growing startups in the animal health industry of the country, complemented by the increasing government support for such companies. For example, in March 2025, MimiBowBow, a Chennai-based startup, introduced India's first AI-powered pet health scan, Pet Scan Pro, enabling pet owners to detect early signs of illness with 95% accuracy using a smartphone.

The moderate impact of the merger & activities on the market can be seen owing to animal health companies in the country venturing into diversifying their product portfolio by acquiring niche animal health products manufacturers. For instance, in September 2024, SeQuent Scientific announced an INR 8,000 crore (USD 933 Mn) merger with Viyash Life Sciences to form one of India's largest animal pharmaceutical platforms.

The Government of India’s proactive regulatory role in animal healthcare is strengthening through updated standards aligned with international norms and strategic partnerships with organizations like the FAO and the UN. Recent initiatives—including the revised Livestock Health and Disease Control Programme with anINR3,880 crores (USD 453 Mn) budget, elimination of outdated safety tests, and AI-enabled vaccine monitoring via a DAHD-UNDP MoU—reflect a comprehensive approach to improving disease control, enhancing veterinary service delivery, and promoting humane, science-based practices. These measures, supported by large-scale vaccination drives, mobile veterinary units, and upgraded disease surveillance infrastructure, are transforming India’s animal health landscape toward greater efficiency, inclusivity, and pandemic preparedness.

The impact of product substitutes is estimated to be high. This is due to the fact that, despite the commanding presence of globally leading companies like Zoetis, Boehringer Ingelheim, Merck, Virbac, etc.,a large number of domestic players exist in the country. According to 2022 reports from Pashudhan Praharee, a GoI magazine dedicated to publishing data on the country’s livestock industry, apart from the leading 10 companies, more than 50 domestic players currently operate in the Indian animal health industry.

The industry is subject to moderate-high impact of regional expansion activities by market players. Wherein, international animal health industry leaders, recognizing the expansion opportunities in India, are expanding their business in the country, and on the other hand, domestic companies are expanding their horizons beyond the country’s boundaries. For instance, in February 2025, Mars Inc., the world's largest veterinary clinic owner, entered the Indian market by acquiring a minority stake in a local veterinary business, Crown Veterinary Services. This move signals growing interest from global veterinary practice chains in India's expanding pet care sector.

Product Insights

The pharmaceuticals segment accounted for the largest revenue share of 42.55% in 2024. The segment is further classified into parasiticide, anti-infective, anti-inflammatory, analgesics, and others. The segment’s dominance can be attributed to the increasing prevalence of food-borne diseases, brucellosis, and zoonotic diseases that are potentially hazardous to animals, thus leading to clinical urgency for the use of potent pharmaceuticals and targeted medicines. The analgesics segment under pharmaceuticals is estimated to grow at the highest rate due to increasing pre-operative as well as post-operative applications of these products in veterinary healthcare.

The other segment, containing veterinary telehealth, veterinary software, and livestock monitoring, is anticipated to grow at the fastest CAGR of 24.1% over the forecast period due to several factors. The growing adoption of these systems and growing awareness about the benefits of using software solutions can be attributed to its growth. Furthermore, the prevalence of zoonotic and chronic diseases in animals and the rising adoption of IoT and artificial intelligence (AI) by animal owners are some of the major drivers for the segment's growth. The segment growth is also attributed to the rising usage among veterinarians to seek consultation from the veterinary specialist via telehealth tools to gain advice and insights regarding the care of the animal.

Animal Insights

The production animal segment dominated the market with a revenue share of 79.57% in 2024. The significant market share represented by the segment may be attributed to the presence largest livestock population in the world as well as an increase in the government’s attention on increasing production of animal-derived products, food safety, and sustainability. Total food security is a goal pursued by policymakers, like NITI Aayog, in the country, which promotes large-scale food production and increases the breeding of livestock. The policies are focused on long-term sustainability, which can be achieved by improving productivity and giving more attention to the production animal healthcare.

The companion animal segment is anticipated to growth at the highest growth rate over the forecast period owing to an increase in companion animal ownership, awareness, and demand for efficient animal care. An increase in companion animal ownership is due to the associated health benefits. Consequently, animal-assisted therapy is increasingly preferred as an adjuvant in a number of areas of animal healthcare. In order to maintain the well-being of companion animals, the adoption of pharmaceuticals and vaccines is increasing, thereby serving as a driver for the segment. In addition, a significant rise in companion animal ownership in the developed and developing regions can also be attributed to increasing urbanization and growing disposable income.

End Use Insights

The veterinary hospitals & clinics segment dominated the market with a share of 71.74% in 2024. The presence of in-house laboratories in the veterinary hospitals and clinics is enabling faster diagnosis, helping patients avail of treatment at the earliest. In addition, the results of the clinical tests are easily available, which reduces the delay. Furthermore, the number of visits and time consumed in taking pet patients from one place to another is also saved. Thus, this segment is anticipated to exhibit considerable growth over the forecast period. Availability of a wide range of treatments as well as diagnostic options in veterinary hospitals & clinics is a high-impact rendering driver for this segment.

The point-of-care testing/in-house testing segment is anticipated to growth at the highest growth rate over the forecast period owing to an increase in the number of initiatives undertaken for animal healthcare and availability of cost-efficient measures for disease diagnosis & monitoring. cCRP, fructosamine, phenobarbital, lactate, hemoglobin, fibrinogen, pancreatic lipase, NH3, serum amyloid A (SAA), and T4 tests are some examples of common veterinary point-of-care tests. These factors are anticipated to boost segment growth, as POC testing can help pet parents identify their pets’ health issues earlier, before they become serious or life-threatening.

Distribution Channel

The hospital/clinic pharmacy segment dominated the market with a share of 57.20% in 2024. The substantial share can be attributed to high accessibility and affordability. The Hospital/Clinic Pharmacy segment is expected to grow at a constant rate owing to the increasing prevalence of chronic diseases. Furthermore, hospitals provide advanced treatment products, which are expected to contribute to the overall growth of the hospital segment. The rise in the adoption of companion pets worldwide is driving the segment's growth. Besides, high procedural volume as a consequence of frequent readmission of pets for treatment is one of the factors responsible for growth.

The e-commerce segment is anticipated to growth at the highest growth rate over the forecast period. This can be attributed to various advantages, such as increased convenience for patients not willing to purchase medicines from retail or hospital pharmacies. Moreover, these also facilitate a consistent supply of drugs, as medications can be preordered. Benefits such as these are anticipated to accentuate the demand for e-commerce throughout the forecast period. Technological advancements, along with increasing pet adoption, are the main growth drivers. Increasing internet penetration is strengthening the smartphone-using population across the globe as it allows a better customer experience.

Key India Animal Health Companies Insights

Key players operating in the India animal health market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In January 2025, The National Dairy Development Board (NDDB) of India, a government enterprise, announced the supply of over 339,000 units of various types of animal vaccines to Kenya.

• In January 2025, JK Paper Ltd., which is a part of the paper and packaging industry, acquired Quadragen Vethealth Pvt. Ltd (QVPL), an animal health products company, to expand into a new business sector of veterinary health.

• In August 2024, Boehringer Ingelheim (BI) India and Vvaan Lifesciences Private Ltd announced a partnership for the distribution rights of the former’s pet parasiticide product portfolio. This agreement was signed under BI’s initiative, India Animal Health Accelerated Growth Plan (AGP), to increase their influence in the Indian market.

• In June 2024, Max PetZ hospital in Delhi performed the nation’s first non-invasive heart surgery on a dog using the Transcatheter Edge-to-Edge Repair (TEER) technique.

• In March 2024, scientists from IIT Guwahati completed the technology transfer of their innovative reverse genetic platform to develop vaccines for swine fever vaccine that was employedby BioMed Pvt Ltd for commercialization. This technology has marked launch of India’s first indigenously developed recombinant virus-based for classical swine fever.

India Animal Health Market